Indeed, CDK4/6 inhibitors are approved for the therapy of breast cancer and numerous studies are ongoing in other tumor entities.4,5 However, not all patients benefit from this therapeutic approach so that an intense search for predictive biomarkers as well as for mechanisms of primary or acquired resistance is required.6,7. This evidence concerns the gene CDK4 and neoplasm.